Back to funds
View filing
Versant Venture Management, LLC
hedge fundUpdated 29 days agoManaged by Versant Venture Management, Llc • Latest filing Q2 2026
Portfolio value
$162.6M
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
43.4%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $48M |
| Q2 2023 | $84.3M |
| Q3 2023 | $188.1M |
| Q4 2023 | $388.8M |
| Q1 2024 | $103.1M |
| Q2 2024 | $77.3M |
| Q3 2024 | $63.6M |
| Q4 2024 | $86.7M |
| Q1 2025 | $60.2M |
| Q2 2025 | $82.1M |
| Q3 2025 | $212.5M |
| Q4 2025 | $151.1M |
| Q1 2026 | $141.4M |
| Q2 2026 | $162.6M |
Top holdings
8 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | M MNST Monte Rosa Therapeutics, Inc. | $77M | 3.18M | 47.34% | — |
| 2 | C CRNC Century Therapeutics, Inc. | $29.8M | 12.17M | 18.33% | — |
| 3 | J JBIO Jade Biosciences, Inc. | $22M | 991.8K | 13.55% | — |
| 4 | L LENZ Lenz Therapeutics, Inc. | $15.1M | 2.66M | 9.28% | — |
| 5 | C CTNM Contineum Therapeutics, Inc. | $8.9M | 542.6K | 5.47% | — |
| 6 | C CRSP CRISPR Therapeutics AG | $8.1M | 148.8K | 4.99% | — |
| 7 | S SKYE Skye Bioscience, Inc. | $1.4M | 2.01M | 0.86% | — |
| 8 | T TPST Tempest Therapeutics, Inc. | $299K | 269.8K | 0.18% | — |